Unknown

Dataset Information

Potential antitumor activity of digitoxin and user-designed analog administered to human lung cancer cells.


ABSTRACT:

Background

Cardiac glycosides (CGs), such as digitoxin, are traditionally used for treatment of congestive heart failure; recently they also gained attention for their anticancer properties. Previous studies showed that digitoxin and a synthetic L-sugar monosaccharide analog treatment decreases cancer cell proliferation, increases apoptosis, and pro-adhesion abilities; however, no reports are available on their potential to alter lung cancer cell cytoskeleton structure and reduce migratory ability. Herein, we investigated the anticancer effects of digitoxin and its analog, digitoxigenin-α-L-rhamnoside (D6MA), to establish whether cytoskeleton reorganization and reduced motility are drug-induced cellular outcomes.

Methods

We treated non-small cell lung carcinoma cells (NSCLCs

SUBMITTER: Eldawud R 

PROVIDER: S-EPMC7484221 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature